These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 35842355

  • 1. Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
    Yu W, Du X, Wang W, Lou J, Liu P, Meng L, Jin J.
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e867-e873. PubMed ID: 35842355
    [Abstract] [Full Text] [Related]

  • 2. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
    Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A.
    Blood; 2012 Feb 02; 119(5):1123-9. PubMed ID: 22160483
    [Abstract] [Full Text] [Related]

  • 3. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
    Int J Clin Oncol; 2017 Oct 02; 22(5):972-979. PubMed ID: 28550414
    [Abstract] [Full Text] [Related]

  • 4. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP.
    Cancer; 2016 May 01; 122(9):1398-407. PubMed ID: 26998677
    [Abstract] [Full Text] [Related]

  • 5. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
    Gore L, Kearns PR, de Martino ML, Lee, De Souza CA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, Rabin KR, Sacchi M, Swanink R, Zwaan CM.
    J Clin Oncol; 2018 May 01; 36(13):1330-1338. PubMed ID: 29498925
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
    Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G.
    Am J Hematol; 2016 Sep 01; 91(9):869-74. PubMed ID: 27192969
    [Abstract] [Full Text] [Related]

  • 8. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
    Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A.
    J Clin Oncol; 2016 Jul 10; 34(20):2333-40. PubMed ID: 27217448
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.
    Cancer; 2020 Jan 01; 126(1):67-75. PubMed ID: 31553487
    [Abstract] [Full Text] [Related]

  • 10. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL.
    Clin Ther; 2012 Feb 01; 34(2):272-81. PubMed ID: 22285209
    [Abstract] [Full Text] [Related]

  • 11. Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.
    Ahmed R, Singh R, Kapoor J, Chandra Patra P, Agrawal N, Bhurani D, Halder R.
    Clin Lymphoma Myeloma Leuk; 2023 Feb 01; 23(2):e71-e77. PubMed ID: 36566108
    [Abstract] [Full Text] [Related]

  • 12. [Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase].
    Chen YL, Wang L, Yan GL, Yang ZZ, Huang ZP, Zhang YS, Zhao Z, Wan CC, Bao Y, Xiang H, Yin H, Chen LF, Xiong YY, Meng L, Li WM.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb 14; 40(2):98-104. PubMed ID: 30831623
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
    Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S.
    Int J Hematol; 2014 Feb 14; 99(2):141-53. PubMed ID: 24357015
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China.
    Chen LF, Yuan GL, Zhong ZD, Zou P, Li DJ, Bao Y, Ren HB, Meng L, Li WM.
    Curr Med Sci; 2018 Dec 14; 38(6):1005-1011. PubMed ID: 30536062
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y, Pan LQ, Qian SX, Song P, Yu H, Zhang SJ, Ge Z, Hong M, Tian T, Li JY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun 14; 21(3):581-6. PubMed ID: 23815902
    [Abstract] [Full Text] [Related]

  • 16. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.
    Leukemia; 2008 Jun 14; 22(6):1200-6. PubMed ID: 18401416
    [Abstract] [Full Text] [Related]

  • 17. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
    Dou XL, Yu L, Qin YZ, Shi HX, Lai YY, Hou Y, Huang XJ, Jiang Q.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov 14; 40(11):924-931. PubMed ID: 31856442
    [Abstract] [Full Text] [Related]

  • 18. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
    Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H.
    Am J Hematol; 2022 Nov 14; 97(11):1413-1418. PubMed ID: 36054032
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R.
    Health Technol Assess; 2012 Nov 14; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [Abstract] [Full Text] [Related]

  • 20. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
    Murai K, Yamaguchi K, Ito S, Miyagishima T, Shindo M, Wakasa K, Inomata M, Nagashima T, Kondo T, Fujimoto N, Yamamoto S, Yonezumi M, Oyake T, Kowata S, Tsukushi Y, Mine T, Meguro K, Ikeda K, Watanabe R, Saito S, Sato S, Tajima K, Chou T, Kubo K, Oba K, Sakamoto J, Ishida Y, The Inter-Michinoku Dasatinib Study Group (IMIDAS).
    Eur J Haematol; 2018 Jan 14; 100(1):27-35. PubMed ID: 28895203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.